BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to CAL27 cell line is 241
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ITGA6 | 6142 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.6 | 0.0265 | 23903875 |
| ITGA6 | 6142 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.6 | 0.0265 | 23903875 |
| ITGA6 | 6142 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by qRT-PCR and FACs and Western Blotting | NA | 0.6 | 0.0265 | 24112466 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by qRT-PCR and FACs and Western Blotting | NA | 0.6 | 0.7582 | 24112466 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | IF staining and Western Blotting followed by SFA | NA | 0.6 | 0.7582 | 31399556 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.7582 | 28093940 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.6 | 0.7582 | 27380877 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.6 | 0.7582 | 27380877 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.6 | 0.7582 | 27380877 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.7582 | 25588898 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | FACs followed by SFA | NA | 0.6 | 0.7582 | 34795388 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 27965308 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs | NA | 0.6 | 0.7582 | 27108536 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | SFA followed by FACs | NA | 0.6 | 0.7582 | 27108536 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by FACs | NA | 0.6 | 0.7582 | 27108536 |
| PROM1 | 9454 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | SFA followed by FACs | NA | 0.6 | 0.7582 | 27108536 |
| IL6 | 6018 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | ELISA followed by Western Blotting | NA | 0.56 | 0.0191 | 28978005 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 1 | 31399556 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 1 | 29575240 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | qRT-PCR and IF staining followed by CFA | NA | 0.52 | 1 | 23627635 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | Western Blotting and FACs followed by SFA | NA | 0.52 | 1 | 34795388 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting and FACs | NA | 0.52 | 1 | 31585633 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.52 | 1 | 34502158 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and Western Blotting | NA | 0.52 | 1 | 32194902 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.52 | 1 | 23903875 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 1 | 24112466 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | FACs followed by SFA and CFA | NA | 0.52 | 1 | 27380877 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | FACs followed by SFA and CFA | NA | 0.52 | 1 | 27380877 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | FACs followed by SFA and CFA | NA | 0.52 | 1 | 27380877 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs | NA | 0.52 | 1 | 27108536 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | SFA followed by FACs | NA | 0.52 | 1 | 27108536 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by FACs | NA | 0.52 | 1 | 27108536 |
| CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | SFA followed by FACs | NA | 0.52 | 1 | 27108536 |
| KLF4 | 6348 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.0891 | 29575240 |
| KLF4 | 6348 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.52 | 0.0891 | 31585633 |
| MYC | 7553 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.1304 | 29575240 |
| MYC | 7553 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.52 | 0.1304 | 31585633 |
| MYC | 7553 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.1304 | 28093940 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.6448 | 29575240 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 34502158 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting and SFA | NA | 0.52 | 0.6448 | 25871396 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 31399556 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 34795388 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and Western Blotting | NA | 0.52 | 0.6448 | 32194902 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31585633 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 24112466 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28093940 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.52 | 0.6448 | 27380877 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.52 | 0.6448 | 27380877 |
| POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.52 | 0.6448 | 27380877 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by IF staining and SFA | NA | 0.52 | 0.5695 | 29575240 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 34502158 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting and SFA | NA | 0.52 | 0.5695 | 25871396 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 34795388 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and Western Blotting | NA | 0.52 | 0.5695 | 27108536 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.52 | 0.5695 | 27380877 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.52 | 0.5695 | 27380877 |
| SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.52 | 0.5695 | 27380877 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 25588898 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 26000099 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting and SFA | NA | 0.48 | 0.5461 | 25871396 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 34795388 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by IHC staining | NA | 0.48 | 0.5461 | 23903875 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 24112466 |
| NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 28093940 |
| ITGB4 | 6158 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0074 | 23903875 |
| NOMO1 | 30060 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0011 | 23903875 |
| ITGB4 | 6158 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0074 | 23903875 |
| NOMO1 | 30060 | HTM/LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0011 | 23903875 |
| ALCAM | 400 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.28 | 0.0583 | 23903875 |
| CTNNB1 | 2514 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.28 | 0.0647 | 23903875 |
| CTNNB1 | 2514 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.28 | 0.0647 | 27965308 |
| ALCAM | 400 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0583 | 23903875 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.684 | 31399556 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | Western Blotting followed by SFA | NA | 0.28 | 0.684 | 34795388 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and Western Blotting | NA | 0.28 | 0.684 | 27108536 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.684 | 34502158 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | FACs followed by SFA and CFA | NA | 0.28 | 0.684 | 27380877 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | FACs followed by SFA and CFA | NA | 0.28 | 0.684 | 27380877 |
| ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | FACs followed by SFA and CFA | NA | 0.28 | 0.684 | 27380877 |
| BMI1 | 1066 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | Western Blotting followed by SFA | NA | 0.28 | 0.1135 | 34795388 |
| BMI1 | 1066 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and Western Blotting | NA | 0.28 | 0.1135 | 27108536 |
| BMI1 | 1066 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and Western Blotting | NA | 0.28 | 0.1135 | 32194902 |
| CTNNB1 | 2514 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 31585633 |
| FOS | 3796 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting and SFA | NA | 0.28 | 0.0053 | 27965308 |
| HDAC1 | 4852 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 26000099 |
| HDAC2 | 4853 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 26000099 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0477 | 25588898 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.28 | 0.0477 | 27380877 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.28 | 0.0477 | 27380877 |
| NOTCH1 | 7881 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.28 | 0.0477 | 27380877 |
| STAT3 | 11364 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0223 | 34502158 |
| TAFAZZIN | 11577 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 31399556 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by IHC staining | NA | 0.24 | 0.1739 | 23903875 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | SFA followed by qRT-PCR | NA | 0.24 | 0.1739 | 24112466 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.24 | 0.1739 | 27380877 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.24 | 0.1739 | 27380877 |
| ABCG2 | 74 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.24 | 0.1739 | 27380877 |
| EPCAM | 11529 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by IHC staining | NA | 0.24 | 0.211 | 23903875 |
| ITGB1 | 6153 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by IHC staining | NA | 0.24 | 0.018 | 23903875 |
| NES | 7756 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by IHC staining | NA | 0.24 | 0.0573 | 23903875 |
| PTK7 | 9618 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.2 | 0.0032 | 23903875 |
| ABCB1 | 40 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0604 | 27380877 |
| ABCB1 | 40 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0604 | 27380877 |
| ABCB1 | 40 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0604 | 27380877 |
| BIRC5 | 593 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | 5-Fluorouracil | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0053 | 27380877 |
| BIRC5 | 593 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Cisplatin | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0053 | 27380877 |
| BIRC5 | 593 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | Docetaxel | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0053 | 27380877 |
| CSPG4 | 2466 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0032 | 28093940 |
| PTK7 | 9618 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | qRT-PCR and CFA followed by SFA and Migration assay | NA | 0.2 | 0.0032 | 30348980 |
| SMO | 11119 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0212 | 28093940 |
| ACSL3 | 3570 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| ACSL4 | 3571 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| ACTR1A | 167 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| AGPS | 327 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| AIFM1 | 8768 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| ALDH18A1 | 9722 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ARHGEF11 | 14580 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ATP1A1 | 799 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| ATP1A2 | 800 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ATP1A3 | 801 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ATP2B1 | 814 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| ATP4A | 819 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ATP6V1A | 851 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| BSG | 1116 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| CA6 | 1380 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| CADM1 | 5951 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| CANX | 1473 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 23903875 |
| CAP1 | 20040 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| CAPN2 | 1479 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| CAT | 1516 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| CAVIN1 | 9688 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| CCT3 | 1616 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| CD109 | 21685 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 23903875 |
| CDH1 | 1748 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 23903875 |
| CKAP4 | 16991 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| CLTC | 2092 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| CNTN1 | 2171 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| COL6A3 | 2213 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| COPB2 | 2232 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| CSTF3 | 2485 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| CTNNA1 | 2509 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| CTNNA3 | 2511 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| CTNND1 | 2515 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| CTTN | 3338 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| DLST | 2911 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| DSG2 | 3049 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| DYSF | 3097 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| EGFR | 3236 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 23903875 |
| ENO1 | 3350 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0095 | 23903875 |
| EPB41L2 | 3379 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ESYT1 | 29534 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| EZR | 12691 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 23903875 |
| FBLN1 | 3600 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| GFM1 | 13780 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| GPI | 4458 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| GPNNB | NA | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| GSN | 4620 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 23903875 |
| HPX | 5171 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| HSP90AA1 | 5253 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 23903875 |
| HSPA2 | 5235 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| HSPA6 | 5239 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 23903875 |
| HSPA7 | 5240 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| HSPA8 | 5241 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0085 | 23903875 |
| HUWE1 | 30892 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| HYOU1 | 16931 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| IGF2BP1 | 28866 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 23903875 |
| IMMT | 6047 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| IQGAP1 | 6110 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 23903875 |
| ITGA2 | 6137 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0106 | 23903875 |
| JUP | 6207 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| KARS1 | 6215 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| KTN1 | 6467 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| LAMB3 | 6490 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 23903875 |
| LMNA | 6636 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 23903875 |
| LRPPRC | 15714 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 23903875 |
| LSS | 6708 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| MARCKS | 6759 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| MOGS | 24862 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| MSN | 7373 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 23903875 |
| MYOF | 3656 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| NCAM1 | 7656 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 23903875 |
| NT5E | 8021 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0095 | 23903875 |
| NUP155 | 8063 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| P4HB | 8548 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| PDIA4 | 30167 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 23903875 |
| PDIA6 | 30168 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| PGDP2 | 39144 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| PKM2 | 9021 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| PLCB3 | 9056 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| PLEC | 9069 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 23903875 |
| PLOD1 | 9081 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| PLOD2 | 9082 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 23903875 |
| PLOD3 | 9083 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 23903875 |
| PLS3 | 9091 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| PLXNB2 | 9104 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| POTEF | 33905 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| PTGS1 | 9604 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| PTPRF | 9670 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| RDX | 9944 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| RPN1 | 10381 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| RPN2 | 10382 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| RPSA | 6502 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 23903875 |
| RRBP1 | 10448 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| SCFD1 | 20726 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| SDHA | 10680 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 23903875 |
| SEC23A | 10701 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 23903875 |
| SERBP1 | 17860 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| SERPINB3 | 10569 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 23903875 |
| SERPINB5 | 8949 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 23903875 |
| SERPINH1 | 1546 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 23903875 |
| SHMT2 | 10852 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| SLC3A2 | 11026 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0085 | 23903875 |
| SLCO5A1 | 19046 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| STOML2 | 14559 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| TCP1 | 11655 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 23903875 |
| TFRC | 11763 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 23903875 |
| TPR | 12017 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 23903875 |
| UBR4 | 30313 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| UGGT1 | 15663 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 23903875 |
| VPS35 | 13487 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ZC3HC1 | 29913 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 23903875 |
| ADAM15 | 193 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 27965308 |
| ATXN1 | 10548 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 27965308 |
| CXCL8 | 6025 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 27965308 |
| DUSP8 | 3074 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 27965308 |
| FOSB | 3797 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 27965308 |
| GAB2 | 14458 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 27965308 |
| HES1 | 5192 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0095 | 27965308 |
| IGFBP1 | 5469 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 27965308 |
| IP6K1 | 18360 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 27965308 |
| IRAK4 | 17967 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 27965308 |
| KRT17 | 6427 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 27965308 |
| MKNK2 | 7111 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 27965308 |
| NUMA1 | 8059 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 27965308 |
| PIP5K1A | 8994 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 27965308 |
| PKD1 | 9008 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 27965308 |
| SGK1 | 10810 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 27965308 |
| TIMM8B | 11818 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 27965308 |
| TNFAIP3 | 11896 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 27965308 |
| TP53BP2 | 12000 | HTM | Head and Neck Cancer | Squamous Cell Carcinoma | CAL27 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 27965308 |